Lobaplatin |
| Catalog No.GC61000 |
Le lobaplatine (D-19466) est un mélange diastéréométrique de complexe de platine (II). Le lobaplatine arrête le cycle cellulaire en phase G1 et G2/M. Le lobaplatine induit l'apoptose en augmentant l'expression de la caspase et de Bax, en diminuant l'expression de Bcl-2. Le lobaplatine peut être utilisé pour la recherche sur le cancer.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 135558-11-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Lobaplatin (D-19466) is a diastereometric mixture of platinum(II) complexes. Lobaplatin (D-19466) shows activity for a variety of tumour types and is a promising antitumour chemotherapeutic agent[1][2].
[1]. Cao H, et al. Lobaplatin Inhibits Prostate Cancer Proliferation and Migration Through Regulation of BCL2 and BAX. Dose Response. 2019 Jun 5;17(2):1559325819850981. [2]. McKeage MJ, et al. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs. 2001 Jan;10(1):119-28.
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *